Cerevel Therapeutics Investor Relations Material
Latest events
Q3 2023
Cerevel Therapeutics
Q1 2024
8 May, 2024
Q4 2023
27 Feb, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Cerevel Therapeutics Holdings Inc
Access all reports
Cerevel Therapeutics Holdings Inc. is a biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders. The company specializes in targeting brain receptor systems to address conditions such as Parkinson’s disease, schizophrenia, and epilepsy. Cerevel Therapeutics Holdings Inc. is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
CERE
Country
🇺🇸 United States